Opendata, web and dolomites
H2020 projects about "tumour"
The page lists 324 projects related to the topic "tumour".
| # | |||
|---|---|---|---|
| 1 | APERIM | APERIM: Advanced bioinformatics platform for PERsonalised cancer IMmunotherapy | 2015 |
| 2 | PROCROP | Professional cross-priming for ovary and prostate cancer | 2015 |
| 3 | MoTriColor | Molecularly guided trials with specific treatment strategies in patients with advanced newly molecular defined subtypes of colorectal cancer (MoTriColor) | 2015 |
| 4 | CRCStemCellDynamics | Molecular Subtype Specific Stem Cell Dynamics in Developing and Established Colorectal Cancers | 2015 |
| 5 | Crosstag | Unravelling cross-presentation pathways using a chemical biology approach | 2015 |
| 6 | A CACTUS | Antibody-free method for Counting All Circulating TUmour cellS while maintaining them alive and intact | 2015 |
| 7 | AdapTT | Real time therapy planning for Thermal based therapy modalities in oncology care. | 2015 |
| 8 | IMMUNOSHAPE | Development of Selective Carbohydrate Immunomodulators Targeting C-type Lectin Receptors on Antigen Presenting Cells | 2015 |
| 9 | PRISAR | Preclinical Intra-Operative Image-Guided Surgery and Post-Operative Radiotherapy of Tumours | 2015 |
| 10 | VIBRA | Very fast Imaging by Broadband coherent RAman | 2015 |
| 11 | COMBPDCHEMOTHERAPY | Rational design of combined PDT photosensitizers and chemotherapeutic agent as new approach in cancer therapy: a computational approach | 2015 |
| 12 | miROMeS | miRNA biomarkers of Osseous Metastases in Serum from breast cancer patients | 2015 |
| 13 | Cdc42Adhere | Role of Cdc42 in cancer cell adhesion to endothelial cells and platelets | 2015 |
| 14 | Tolltum | Role, regulation and targeting of nucleic acid-sensing TLRs within the tumour microenvironment | 2015 |
| 15 | NextGen RiBiomics | Next Generation Proteomic Analysis of Pre-Ribosomal Proteome Dynamics Coupled to Glucose Metabolism in Caner Cells | 2016 |
| 16 | STROMAMECH | Targeting stromal cells to modify tumor mechanical microenvironment and optimize drug delivery | 2015 |
| 17 | DC cancer | Development and immunological control of dendritic cell cancer | 2015 |
| 18 | AuNP-PhotoBioDrug | Functionalized AuNPs and their use for biological applications | 2015 |
| 19 | breast cancer dormancy | Molecular characterisation of a clinical model of estrogen receptor-positive breast cancer dormancy | 2015 |
| 20 | MHAtriCell | Hyaluronan-rich matrices crosslinked with collagen-like peptides for 3D culture of ovarian cancer cells | 2015 |
| 21 | GENMETASTEM | GENOMIC AND METABOLIC REGULATION OF METASTATIC CANCER STEM CELLS | 2016 |
| 22 | MACROIMAGING | Specific Fluorogenic Peptides for Imaging Metastasis-associated Macrophages | 2015 |
| 23 | VesSenDrugDeliv | A versatile platform for the design of targeting drug delivery vesicles | 2015 |
| 24 | CICCI | Characterization of Intestinal Cancer Cell Invasion | 2015 |
| 25 | APOBEC | Enzymatic DNA deamination and the immunity/cancer balance | 2015 |
| 26 | WntTraffic | Characterising the spatial organisation and regulation of the Wnt receptor complex in stem cells and cancer | 2016 |
| 27 | BRCA2Interact | Structural and biochemical characterization of pre-recombination complexes | 2015 |
| 28 | NANOTAM | Development and Evaluation of Nanomedicines for Cancer Treatment through Immunomodulation: Targeting Tumor-Associated Macrophages | 2015 |
| 29 | PREVENT | Prostate cancer extracellular vesicles as biomarkers for nanomedicine treatment | 2015 |
| 30 | RAIL | Radiomics of lung cancer (RAIL): non-invasive stratification of tumour heterogeneity for personalised cancer therapy | 2015 |
| 31 | ER_disease | Defining hormonal cross-talk and the role of mutations in estrogen receptor positive breast cancer | 2015 |
| 32 | MELGEN | MELanoma GENetics - understanding and biomarking the genetic and immunological determinants of melanoma survival | 2015 |
| 33 | CSC-IS | Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. | 2015 |
| 34 | SPICE | Synthetic Lethal Phenotype Identification through Cancer Evolution Analysis | 2015 |
| 35 | DNA2REPAIR | DNA strand break repair and links to human disease | 2015 |
| 36 | ISPIC | Image-Guided Surgery (IGS) and Personalised Postoperative Immunotherapy To Improving Cancer Outcome | 2016 |
| 37 | TOPOmics | Global dynamics of topoisomerase-induced DNA breaks | 2015 |
| 38 | RNAEDIT | RNA EDITING IN HEALTH AND DISEASE | 2016 |
| 39 | CELLPLASTICITY | New Frontiers in Cellular Reprogramming: Exploiting Cellular Plasticity | 2015 |
| 40 | ONCOCHECK | A simple blood test to monitor disease progression in patients undergoing cancer therapy | 2015 |
| 41 | UNIBIO | TK210 ELISA – universal serum protein biomarker for cancer screening, diagnosis, treatment response monitoring and early detection of relapse (UNIBIO) | 2015 |
| 42 | CYTOPRO | Profiling of tumour cells in blood for personalized treatment of metastatic cancer | 2015 |
| 43 | HEP-CAR | Mechanisms underlying hepatocellular carcinoma pathogenesis and impact of co-morbidities. | 2016 |
| 44 | GLINT | GlucoCEST Imaging of Neoplastic Tumours | 2016 |
| 45 | UM Cure 2020 | New therapies for uveal melanoma | 2016 |
| 46 | FORCE | Imaging the Force of Cancer | 2016 |
| 47 | ChiLTERN | Children’s Liver Tumour European Research Network | 2016 |
| 48 | H2020MM04 | DC-based immunotherapy to treat Malignant Mesothelioma | 2016 |
| 49 | CONQUEST | Companion Nanodiagnostics for Quantifying EPR and Stratifying Patients to Targeted Nanotherapies | 2016 |
| 50 | ReTuBi | Towards outstanding research and training in tumour biology at IMM | 2016 |
| 51 | OncoMasTR | OncoMasTR - Novel Prognostic Assay for Early Stage Breast Cancer | 2016 |
| 52 | FourCmodelling | Conflict, Competition, Cooperation and Complexity: Using Evolutionary Game Theory to model realistic populations | 2016 |
| 53 | PrECISE | PERSONALIZED ENGINE FOR CANCER INTEGRATIVE STUDY AND EVALUATION | 2016 |
| 54 | LDC4PCaTher | BMX-targeted ligand-drug conjugates for prostate cancer therapy | 2016 |
| 55 | ThruBlood | Clinical validation of Trop-2 as a serum biomarker for monitoring of disease-course in patients affected by breast and colon cancer | 2016 |
| 56 | TARG-SUP | Targeting TGF-β activation, likely the core mechanism of immunosuppression by human regulatory T cells. | 2016 |
| 57 | PRECIOUS | Scaling-up biodegradable nanomedicines for multimodal for multimodal precision cancer immunotherapy | 2016 |
| 58 | IMAGINE | Widefield Raman imaging probe for intraoperative margin assessment of cancers | 2016 |
| 59 | EPILIPRO | Elucidating the role of Arid1a in adult liver | 2016 |
| 60 | MCNTMTDC | Metabolic control on NF-κB activity during dendritic cells-mediated immune tolerance to tumours | 2017 |
| 61 | iGEMMdev | Development and Characterisation of New Immunogenic GEMMs of Lung Cancer | 2017 |
| 62 | MPSC | Membrane Potential and Stem Cell Potency in Normal and Malignant Tissues | 2016 |
| 63 | NuSiCC | Modelling the therapeutic potential of NUAK1 suppression in colorectal cancer | 2016 |
| 64 | ENDYVE | ENgineering DYnamic ViscoElasticity to study cell response | 2016 |
| 65 | RAMSES | Aryl amide metallofoldamersas selective saccharide sensors | 2016 |
| 66 | AVITAG | Alphaviral Immunotherapy against Glioblastoma | 2016 |
| 67 | GENDER-CF | Gender-related differences in expression of microRNAs in cystic fibrosis | 2017 |
| 68 | CIRCLE | Investigation of the role of CYLD in Chronic Lymphocytic Leukaemia | 2016 |
| 69 | HeartAtaK | Targeting the Anti-Target: From Structure to Drug in the heart Kv11.1 channel | 2016 |
| 70 | HeteroCancerInvasion | Effect of heterogeneity of cancer cells on collective invasion | 2016 |
| 71 | OMIS | Feasibility study on Opto-Magnetic Imaging Spectroscopy for cancer screening | 2016 |
| 72 | OSTEOMET | Clinical Validation of a Novel Biomarker for the Prediction of Bone Metastasis in Early Stage Breast and Prostate Cancer | 2016 |
| 73 | TSGPs-of-CFSs | Role of Tumour Suppressor Gene Products of Common Fragile Sites in Human Diseases | 2016 |
| 74 | NanoPokers | Deciphering cell heterogeneity in tumors using arrays of nanowires to controllably poke single cells in longitudinal studies | 2016 |
| 75 | ONCOINTRABODY | Targeting common oncogenes with intracellular monobodies | 2016 |
| 76 | DECODE | Allele-specific Deconvolution of Tumour DNA Methylation and Expression Data toReveal Underlying Cell Populations | 2016 |
| 77 | FLUORODRUGS | Smart Theranostic Agents for the Tumour Microenvironment | 2017 |
| 78 | ASTONISH | Advancing Smart Optical Imaging and Sensing for Health | 2016 |
| 79 | Lumiblast | A paradigm shift in cancer therapy – using mitochondria-powered chemiluminescence to non-invasively treat inaccessible tumours | 2016 |
| 80 | FIBROCAN | Defining the immunological interplay between fibroblastic reticular cells and anti-tumour T cells | 2016 |
| 81 | NANOTER | Development of Ultra-Sensitive Nanotherapeutic Anticancer Agents for Boron Neutron CaptureTherapy | 2016 |
| 82 | iGOLDD | Commercialising MR-HIFU: an Image-Guided Local Drug-Delivery Platform | 2016 |
| 83 | CHEMCHECK | CHECKPOINTS IN CHECK: Novel Chemical Toolbox for Local Cancer Immunotherapy | 2016 |
| 84 | LeukaemiaTargeted | Selecting genetic lesions with essential function for patients' leukaemia in vivo as targets for precision medicine | 2016 |
| 85 | BCM-UPS | Dissecting the role of the ubiquitin proteasome system in the pathogenesis and therapy of B-cell malignancies | 2016 |
| 86 | GBM-CPP | Developing an anti-Myc cell-penetrating peptide for cancer treatment | 2016 |
| 87 | GlioDx | GlioDx - Blood platelet-based monitoring and treatment optimisation for glioblastoma patients | 2016 |
| 88 | INTHER | Clinical validation and commercialization of innovative immunostimulating Interstitial Laser Thermotherapy | 2016 |
| 89 | Project ACT | Automated autologous cell therapy system | 2016 |
| 90 | NO-META | Feasibility study of a NOvel METAbolic liquid biopsy for cancer therapy monitoring | 2016 |
| 91 | Syndivia | Next generation drug conjugates for cancer treatment | 2016 |
| 92 | MYELOMANEXT | Integrated next-generation flow cytometry and sequencing to uncover the pathway of curability in multiple myeloma | 2016 |
| 93 | MATRICAN | Matrix during cancer progression | 2016 |
| 94 | SYNOX | Total Synthesis of Biologically Important Pyrrolidinone Natural Products and Analogues Thereof. | 2016 |
| 95 | ADC | Next-Generation Antibody-Drug Conjugates for safer and more effective cancer therapies | 2016 |
| 96 | HiPerNav | High Performance Soft-tissue Navigation | 2016 |
| 97 | BITCAT | Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy | 2017 |
| 98 | HypoSens | Nano-confined photonic system for detection of breast cancer spread to the lymph nodes | 2016 |
| 99 | MMpredict | Validation of a personalised medicine tool for Multiple Myeloma that predicts treatment effectiveness in patients | 2016 |
| 100 | McHAP | Entrapment of Hypoxic Cancer by Macrophages Loaded with HAP | 2017 |
| 101 | NONCODRIVERS | Finding noncoding cancer drivers | 2016 |
| 102 | HYPOXIMMUNO | Tackling the Achilles Heel of Immunotherapy: Validating imaging biomarkers and targeting the immunological niche of tumour hypoxia | 2016 |
| 103 | MECHANO-CONTROL | Mechanical control of biological function | 2017 |
| 104 | LungCARD | Blood test for clinical therapy guidance of non-small cell lung cancer patients | 2017 |
| 105 | EURE-CART | EURopean Endeavour for Chimeric Antigen Receptor Therapies | 2017 |
| 106 | IMMUNOSABR | Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer | 2017 |
| 107 | MONONANOCHEM | In vivo engineering of monocytes loaded with nano-chemotherapeutic formulations: a novel live-cell mediated drug delivery system for the treatment of cancer | 2017 |
| 108 | MetResistance | The role of tumour microenvironment in metastatic hormone-refractory prostate cancer | 2017 |
| 109 | SpheroPredict | A 3D advanced test for prediction of drug response in secondary liver cancer | 2017 |
| 110 | PDClungSME1 | A therapeutic vaccine candidate for lung cancer based on an exclusive cell line of Plasmacytoid Dendritic Cells (PDC*line) | 2016 |
| 111 | INNOBCT | Innovative combination therapy against bladder cancer | 2017 |
| 112 | COLGENES | Defining novel mechanisms critical for colorectal tumourigenesis | 2017 |
| 113 | Curtana | Patented small molecule therapeutics that target cancer stem cells for the treatment of glioblastoma and other brain cancers | 2017 |
| 114 | BGCI | Bacterial Ghost Cancer Immunotherapy - A new standard in tumour therapy based on the bacterial ghost platform technology | 2017 |
| 115 | BRECASTEM | Functional and Molecular Characterisation of Breast Cancer Stem Cells | 2017 |
| 116 | GlycoModels | 3D glyco-engineered models to address the role of glycosylation in gastric cancer clinical management | 2017 |
| 117 | Survive | Surviving metabolism: acid handling and signalling | 2017 |
| 118 | CMI2T IA | Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs | 2017 |
| 119 | BCSC-ST | Breast cancer stem-like cells specific vulnerabilities: focus in HER2 over-expression and protein glycosylation | 2017 |
| 120 | ExoSensor | A Nano-photoelectric Exosome Biosensor for Point-of-care Diagnosis of Early-stage Cancer | 2017 |
| 121 | TSPO METALLODRUGS | Novel, highly effective and selective anticancer metallodrugs | 2018 |
| 122 | IMMUNO_CRC | Microbiota-immune interaction in colorectal cancer | 2017 |
| 123 | SCALTIE | Single cell analysis of the lung tumour-immune ecosystem: Developing new tools for effective immunotherapy | 2017 |
| 124 | NANOCANCER | Getting new insights into the radio-sensitization effects of nanoparticles in photon and charged particle therapy | 2017 |
| 125 | DNAmethAML | Investigation of aberrant DNA methylation in malignant haematopoiesis | 2018 |
| 126 | GLIOMA | Targeting Glioblastoma using Combinatorial Therapeutic Nanovaccine | 2017 |
| 127 | HIPPOCRATE | Hybrid Imaging of PET and PrOmpt gamma for preCision RAnge- and biological- guidance in proton ThErapy | 2017 |
| 128 | OPN-Can | Investigating the role of OPN-CD44 in mechanosensitive tumour invasion using biomimetic models | 2017 |
| 129 | DevoSignGammaDelta | Tracking γδ T cell development and TCRγδ proximal signalling | 2018 |
| 130 | GlimS | Patient-specific tumour growth model for quantification of mechanical 'markers' in malignant gliomas: Implications for treatment outcomes. | 2017 |
| 131 | SIOMICS | SIngle-cell multi-OMICs approach to study intra-tumour heterogeneity of soft tissue Sarcomas | 2017 |
| 132 | TEMPOMATH | Temporal delays in mathematical models of cell biology processes | 2017 |
| 133 | IVORIaN | RAS/C-RAF interaction: A new pharmacological target in Kras-driven lung cancer. | 2017 |
| 134 | TNFaLysMyr | Unique TNFα lysine myristoylation; elucidating its function, regulation and integration into inflammation | 2018 |
| 135 | SPLICANCER | Regulation and reprogramming of alternative splicing in cellular transformation | 2017 |
| 136 | METMEL | Long range-acting drivers of premetastatic niches in melanoma | 2017 |
| 137 | METCLL | Discovery and validation of ‘epidrivers’ of cancer evolution and resistance to therapy | 2018 |
| 138 | DSMT16 | Deciphering causes and consequences of inflammation in subtypes of sporadic intestinal cancer | 2018 |
| 139 | WHOLENICHE | Hold it or let it go: a niche decision on cancer growth | 2017 |
| 140 | PHRD | The development of Personalised Host Response Diagnostic kit | 2017 |
| 141 | BEAT | The functional interaction of EGFR and beta-catenin signalling in colorectal cancer: Genetics, mechanisms, and therapeutic potential. | 2017 |
| 142 | NEST | Nanoengineering of radioactive seeds for cancer therapy and diagnosis | 2017 |
| 143 | NanoMOFdeli | Design of NanoMOFs Capsules for Drug Delivery and Bioimaging. | 2017 |
| 144 | META-DORM | Mechanobiology of METAstatic and DORMant cancer cells in bone marrow lesions | 2018 |
| 145 | altEJrepair | Characterisation of DNA Double-Strand Break Repair by Alternative End-Joining: Potential Targets for Cancer Therapy | 2017 |
| 146 | SIRMIO | Small animal proton Irradiator for Research in Molecular Image-guided radiation-Oncology | 2017 |
| 147 | gdTCR-Ligand | Investigating the recognition of a novel ligand by gamma-delta T cells and the translation of this interaction into molecules for future cancer immunotherapy | 2017 |
| 148 | MetaboMARKER | A metabolism-based prognostic biomarker for prostate cancer | 2017 |
| 149 | cis-CONTROL | Decoding and controlling cell-state switching: A bottom-up approach based on enhancer logic | 2017 |
| 150 | Secret Surface | The cell surface tetraspanin web drives tumour development and alters metabolic signalling | 2017 |
| 151 | HoldCancerBack | What Holds Cancer Cells Back? | 2017 |
| 152 | STEPUP | Synthetic DCs for a T cEll ProdUction Platform | 2017 |
| 153 | CHAMPP | Czech Hamburg Advanced Medical and Photonics Project | 2017 |
| 154 | Tumor-Treg-Targeting | Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours | 2018 |
| 155 | u-PBeam | Microdosimetry study of a new radiation therapy method based on proton minibeams | 2017 |
| 156 | CADENCE | Catalytic Dual-Function Devices Against Cancer | 2017 |
| 157 | REACT | Optimising Radiomics for MRI-based personalised cancer treatment | 2017 |
| 158 | CuHypMECH | New Nuclear Medicine Imaging Radiotracer 64Cu(II) for diagnosing Hypoxia Conditions Based on the Cellular Copper Cycle | 2017 |
| 159 | CONTRA | Computational ONcology TRaining Alliance | 2018 |
| 160 | GLIOTRAIN | Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics | 2017 |
| 161 | PREDICT | A new era in personalised medicine: Radiomics as decision support tool for diagnostics and theragnostics in oncology | 2017 |
| 162 | ESEMT | DETERMINING THE FUNCTIONAL CONSEQUENCES OF TRANSCRIPTIONAL ENHANCER ACTIVATION ON ALTERNATIVE SPLICING DURING EMT | 2017 |
| 163 | TarMyc | Targeting the Oncogenic Function of Myc in vivo | 2018 |
| 164 | BioNanoPattern | Protein nano-patterning using DNA nanotechnology; control of surface-based immune system activation | 2018 |
| 165 | HypoRuLight | Hypoxic Tumour Models for Photoactivatable Ruthenium-based Chemotherapy | 2017 |
| 166 | EDIReX | EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts | 2018 |
| 167 | IMMUNISA | A Next Generation Immunotherapy for Human Papilloma Virus induced Cervical Cancer | 2017 |
| 168 | CylcoRu4PACT | Cyclometallated ruthenium complexes for photo-activated chemotherapy | 2018 |
| 169 | INSITUMUT | Direct detection of cancer-causing mutations in tumour specimens | 2018 |
| 170 | ToMeTuM | Towards the Understanding a Metal-Tumour-Metabolism | 2018 |
| 171 | INTERCELLMED | SENSING CELL-CELL INTERACTION HETEROGENEITY IN 3D TUMOR MODELS:TOWARDS PRECISION MEDICINE | 2018 |
| 172 | CANCER | Personalised Postoperative Immunotherapy To Improving Cancer Outcome and improving quality of life | 2018 |
| 173 | ITHACA | Immuno-targeting of human AML quiescent cells by a novel phage display approach. | 2018 |
| 174 | OMVCRC | Engineered bacterial Outer Membrane Vesicles (OMVs) for colorectal cancer immunotherapy | 2018 |
| 175 | OncoSeq | OncoSeq: an innovative single-cell system for immunomonitoring | 2017 |
| 176 | INTACT | Imaging NM: A Nanoparticulate Precision Medicine Approach to Target Cancer | 2017 |
| 177 | EXACT-dna | EXtended Analysis of Circulating Tumour DNA to improve cancer management strategies | 2017 |
| 178 | INSPIRE | INfraStructure in Proton International REsearch | 2018 |
| 179 | DiSect | The Tumour Stroma as a Driver of Clonal Selection | 2018 |
| 180 | ExoSonic | A microfluidic chip for non-invasive, early detection of pancreatic cancer – liquid biopsy | 2018 |
| 181 | MicroBone | Novel 3D platforms to engineer bone microtissues for in vitro disease models | 2018 |
| 182 | GrowthControl | Mechanical and systemic control of growth during Drosophila abdominal development | 2018 |
| 183 | EDROMA | Novel nanomedicine for the treatment of glioma | 2018 |
| 184 | POLYTHEA | Design and photo-optimization of Photosensitizer for Human Health and Food security applications or “how light can save lives” | 2018 |
| 185 | NIRCOThera | Spatiotemporal, near-infrared light controlled carbon monoxide delivery for cancer immunotherapy | 2018 |
| 186 | MaGMa | Applying Metabolomics to Unveil follow-up treatment biomarkers and Identify Novel TherapeuticTargets in Glioblastoma | 2018 |
| 187 | CellularNanoMachines | Development of Stimuli-Responsive Nanoparticle-carrying T lymphocytes in the Fight against Cancer | 2019 |
| 188 | CENTR-ALL | Clarifying role of the CENTROSOME in abnormal mitotic processes featuring the most commonchildhood malignancy: paediatric High Hyperdiploid Acute Lymphoblastic Leukaemia (HHDpALL) | 2019 |
| 189 | EMBRACE | Elucidating Mechanisms of Bladder Cancer Metastasis | 2018 |
| 190 | PhenoSwitch | Phenotype switching: plasticity and/or differentiation of stromal cells and their progenitors within the tumour microenvironment regulate tumour fate. | 2018 |
| 191 | MicroC | Agent-Based Modelling of Gene Networks to model clonal selection in the tumour microenvironment and predict therapeutic resistance | 2018 |
| 192 | VALSL | Valorisation of splice-switching oligonucleotides for lung cancer therapy | 2018 |
| 193 | SPeNTa-Brain | Synthetic Peptidic Nanovesicles for Targeting Paediatric Brain tumours | 2019 |
| 194 | NanoFEITH | Nanoparticles for Fluorescence-Enhanced Imaging and Therapy of Breast Cancer | 2018 |
| 195 | ORTHOCAT | Bioorthogonal Photocatalytic Activation of Metal-Based Prodrugs | 2018 |
| 196 | MITIG | Addressing MITochondrial Import by Glioblastoma cells to rewire respiratory metabolism | 2019 |
| 197 | OESOPHAGEAL FATE | Epithelial/Mesenchymal Cross-talk in response to injury and early tumorigenesis; a spatiotemporal perspective | 2019 |
| 198 | GLYCANLIPO | Selective glycan recognition using molecularly imprinted liposomes | 2018 |
| 199 | Gal3-BrainMets | A novel immunotherapy against brain metastasis: Anti-Galectin-3 | 2019 |
| 200 | MECoCaM | Human gut Microbiome, gene Expression and Colorectal Cancer: Assigning causal roles from a novel Mendelian randomization perspective. | 2018 |
| 201 | MECHANOIDS | Probing and controlling the three-dimensional organoid mechanobiology | 2019 |
| 202 | MECHANOSITY | Mechanical regulation of cellular behaviour in 3D viscoelastic materials | 2019 |
| 203 | YAP MECHANO | Elucidating the mechanism of mechanotransduction through YAP and TAZ | 2019 |
| 204 | UNNAMEd-2 | Unraveling the conceptional novel ADAM17 regulation by PP2A in metastasis formation. | 2019 |
| 205 | HDAC6_GEMM | Development of a novel genetically engineered mouse model to study the role of HDAC6 in oncogenesis and metastasis of non-small cell lung cancer. | 2018 |
| 206 | PCaProTreat | Multi-omics molecular treatment targets for Prostate Cancer | 2018 |
| 207 | GDCOLCA | Understanding gamma delta T cells in colon cancer metastasis | 2018 |
| 208 | QuanTII | Quantitative T cell Immunology and Immunotherapy | 2018 |
| 209 | THERACAT | Bio-orthogonal catalysis for cancer therapy | 2018 |
| 210 | GLIOGUIDE | Commercialising a novel glioblastoma targeted therapy and a companion diagnostic compound | 2018 |
| 211 | 4DBIOSERS | Four-Dimensional Monitoring of Tumour Growth by Surface Enhanced Raman Scattering | 2018 |
| 212 | EVO-NANO | Evolvable platform for programmable nanoparticle-based cancer therapies | 2018 |
| 213 | HOPE | Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6 | 2018 |
| 214 | DISCOVER | Death receptor signalling in tumour immune editing | 2018 |
| 215 | NovaTests | The first predictive test for radio-sensitivity. A step towards an improved and personalised radiation therapy cancer treatment. | 2018 |
| 216 | EpiGlioT | Epigenetic Glioblastoma Therapeutics | 2018 |
| 217 | SMARTRIOX | Disruptive targeted drug delivery system via synergistic combination of intelligent DNA molecular machines and gated mesoporous nanoparticles | 2018 |
| 218 | Olfactomics | Bringing Surgery to the 21st Century: Feasibility Verification of Real-time Tissue Analysis During Surgery | 2018 |
| 219 | HepatoPredict | A decision tool for Liver Transplantation based on molecular signature | 2018 |
| 220 | SenolT | Fast and effective diagnostic test for the early detection of residual tumours to prevent cancer recurrence | 2018 |
| 221 | TETHIS-SBS-CTC | TETHIS-SBS-CTC: An innovative diagnostic testing platform to identify and characterize circulating tumour cells (CTCs) in blood samples. | 2018 |
| 222 | Simecos | A New Adjuvant Nutraceutical from the North Atlantic Ocean for Breast, Lung and Pancreatic Cancer Patients | 2018 |
| 223 | MINGRAFT | Biomineralizing coatings for maxillofacial implants | 2020 |
| 224 | CL-IO | Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis | 2018 |
| 225 | COCLICAN | COllaborative Consortium for the early detection of LIver CANcer | 2018 |
| 226 | CytoPro | A breakthrough cancer diagnostic instrument to save 3000 years of human lives annually and up | 2018 |
| 227 | OXIGENATED | Hemoglobin based Protein Nanocarriers for Tumour Oxygenation and a more effective Photodynamic Therapy | 2019 |
| 228 | MechanoIMM | Mechanical Immunoengineering for Enhanced T-cell Immunotherapy | 2018 |
| 229 | CANCER INVASION | Deciphering and targeting the invasive nature of Diffuse Intrinsic Pontine Glioma | 2019 |
| 230 | ImmunoCode | Digital Single Cell Immunology: Decoding Cellular Interactions for Improved Immunotherapy | 2018 |
| 231 | DNAProteinCrosslinks | DNA-protein crosslinks: endogenous origins and cellular responses. | 2019 |
| 232 | MarginGuide | The MarginGuide: a medical device to improve the results of cancer surgery | 2018 |
| 233 | PRIMAGE | PRedictive In-silico Multiscale Analytics to support cancer personalized diaGnosis and prognosis, Empowered by imaging biomarkers | 2018 |
| 234 | VeCare | Selective retention of VEGF for cancer and retinopathies therapeutics | 2019 |
| 235 | TUMOURPRINT | High Throughput Bioprinting of Tumour Models for Drug Development and Oncology Research | 2018 |
| 236 | LEGACy | CeLac and European consortium for a personalized medicine approach to Gastric Cancer | 2019 |
| 237 | AI-MICADIS | Artificial Intelligence System for Multi-Cancer Detection Support | 2019 |
| 238 | Mercurius Connect | Mercurius Connect | 2019 |
| 239 | BIOMORPHIC | Brain-Inspired Organic Modular Lab-on-a-Chip for Cell Classification | 2019 |
| 240 | iNANOVAC4CANCER | BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY | 2019 |
| 241 | TCRabX | Structural basis for the therapeutic efficiency of optimal-affinity T cell receptors | 2019 |
| 242 | GLADIATOR | Next-generation theranostics of brain pathologies with autonomous externally controllable nanonetworks: a trans-disciplinary approach with bio-nanodevice interfaces | 2019 |
| 243 | FRINGE | Fluorescence and Reactive oxygen Intermediates by Neutron Generated electronic Excitation as a foundation for radically new cancer therapies | 2019 |
| 244 | CANCEREVO | Deciphering and predicting the evolution of cancer cell populations | 2019 |
| 245 | FanCY | Flow and Deformation of Cancer tumours near Yielding | 2019 |
| 246 | PROTONMBRT | Spatial fractionation of the dose in proton therapy: a novel therapeutic approach | 2019 |
| 247 | iPC | individualizedPaediatricCure: Cloud-based virtual-patient models for precision paediatric oncology | 2019 |
| 248 | HOLOMAN | Holographic acoustic assembly and manipulation | 2019 |
| 249 | GSYNCOR | Graphene-syncronized coherent Raman scattering laser and microscope | 2019 |
| 250 | PICModForPCa | Personalised Image-based Computational Modelling Framework to Forecast Prostate Cancer | 2020 |
| 251 | SYNKIT | Synthetic Natural Killer Cells for Immunotherapy | 2020 |
| 252 | Oncogenic PI3-kinase | New biology of oncogenic PI 3-kinase | 2019 |
| 253 | RESIST3D | Targeting drug resistance in ovarian cancer through large-scale drug-response profiling in physiologically relevant cancer organoids | 2020 |
| 254 | BrEXo-Apt | Non-invasive and accurate diagnosis and treatment of breast cancer. | 2019 |
| 255 | TRACERxTME | Constructing an evolutionary atlas of the immune landscape in lung cancer | 2019 |
| 256 | GLIOHAB | Multiparametric imaging of glioblastoma tumour heterogeneity for supporting treatment decisions and accurate prognostic estimation | 2019 |
| 257 | THERMOGUIDE | Optimizing delivery and effectiveness of chemotherapy in breast cancer patients using thermotherapy under image-guidance | 2019 |
| 258 | EVOMET | The rise and fall of metastatic clones under immune attack | 2019 |
| 259 | MacrophInt | Targeting integrin signaling in tumour-associated macrophages to combat cancer progression and resistance | 2019 |
| 260 | MHT-ImmunoEnhancer | Stimuli-Responsive Nanoplatform to Combine Magnetic Hyperthermia with Immunemodulators Delivery for Glioblastoma Treatment | 2019 |
| 261 | Need2immune | Personalized liposomal cancer vaccines within days by rapid formulation screening | 2019 |
| 262 | EndoPos | Endosome positioning in tumour-stroma interactions | 2019 |
| 263 | BispecificsThatClick | Combinatorial Antibody Synthesis for the Discovery of New Anti-Tumour Immunomodulators | 2019 |
| 264 | TRIDOS | Targeted Radiotherapy Internal Dosimetry: A platform for individualized patient dosimetry and radiobiological assessment | 2019 |
| 265 | PRINT-CHEMO | To develop 3D bioPRINTed osteoinductive constructs that deliver CHEMOtherapeutics within large bone defects that are surgically created when removing bone tumours. | 2019 |
| 266 | CentrosoTME | The role of extra centrosomes on the tumour microenvironment | 2019 |
| 267 | MechTransition | Regulatory mechanisms controlling a new mechanical Epithelial to Mesenchymal Transition in zebrafish | 2020 |
| 268 | PhotoStem | Photoswitching molecules for the spatiotemporal control of cancer stem cells with light | 2019 |
| 269 | PDX-PC | Elucidation of tumour cell plasticity mechanisms associated to treatment in metastatic prostate cancer | 2019 |
| 270 | ARGONAUT | ARGONAUT: from the synthesis of gAnglioside tumouR antiGens to a platfOrm for caNcer Active immUnoTherapy | 2019 |
| 271 | qCHROMDEK | Quantitative insight into chromatin nanoscale structure: sub-nuclear organisation of oncoprotein DEK | 2019 |
| 272 | UreaCa | Deciphering the metabolic roles of the urea-cycle pathway in carcinogenesis for improving diagnosis and therapy | 2019 |
| 273 | CancerADAPT | Targeting the adaptive capacity of prostate cancer through the manipulation of transcriptional and metabolic traits | 2019 |
| 274 | IMMUcan | Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts | 2019 |
| 275 | METASPINE | Comprehensive experimental and computational mechanical characterisation of metastatic vertebrae | 2019 |
| 276 | TargetGBM | Generating a targeted, brain-permeable and stable polymeric nanoparticle for systemic gene delivery to glioblastoma | 2019 |
| 277 | H. Pylori-Scopy | Biophotonic Spectroscopic tool for Helicobacter Pylori diagnosis - a pathway for low cost clinical robotic device | 2019 |
| 278 | TARGLIO | Improved glioblastoma treatment through targeted, local drug delivery | 2019 |
| 279 | QuiescStemGBM | Studying the role of Quiescent Cancer Stem Cells in GBM development using a novel in vivo cell cycle-based approach | 2020 |
| 280 | PROTEUS | Predicting Routes Of Tumour Evolution driven by Unstable genomes and Selection | 2019 |
| 281 | CHyMERA | Monitoring cancer heterogeneity based on the dynamic assessment of the Warburg effect under metabolic perturbation | 2019 |
| 282 | SIMCARE | SImulation-assisted Minimally invasive CAncer tREatment using the gosmart environment | 2019 |
| 283 | Breakborder | Breaking borders, Functional genetic screens of structural regulatory DNA elements | 2019 |
| 284 | UNPACK PD-L1 | Molecular mechanism and inhibition of extracellular vesicle-mediated PD-L1 release in melanoma cells | 2020 |
| 285 | MS | Unravelling the molecular and cellular mechanism of metastasis | 2020 |
| 286 | IMPACT | Improving DNA Analysis for Correct Healthcare | 2019 |
| 287 | U-TURBT | A revolutionary shape memory alloy-based disposable device for bladder cancer removal | 2019 |
| 288 | ARTimmune | Programmable ARTificial immune systems to fight cancer | 2019 |
| 289 | RASImmune | Targeting RAS driven tumour immune evasion | 2019 |
| 290 | APAC | Advanced Pain Control – An innovation in pain control for those suffering from secondary bone cancer | 2019 |
| 291 | Promitil | Promitil® - a new ‘smart’ nanomedicine for cancer chemo-radiotherapy. | 2019 |
| 292 | TK-NEO | Personalized Cancer Immunotherapy through DNA-EP vaccines | 2019 |
| 293 | VISIOCYT | VISIOCYT SCREENING: A DISRUPTIVE ARTIFICIAL INTELLIGENCE SOLUTION FOR BLADDER CANCER SCREENING | 2019 |
| 294 | MechanoGPER | Development of GPER agonists as a novel therapeutic option for pancreatic cancer | 2019 |
| 295 | EndoMapper | EndoMapper: Real-time mapping from endoscopic video | 2019 |
| 296 | NEUcrest | Training European Experts in Multiscale Studies of Neural Crest Development and Disorders: from Patient to Model Systems and Back again. | 2019 |
| 297 | PeptiCHIP | PEPTICHIP: Streamlined identification of tumour neoantigens for personalised anti-cancer immunotherapy | 2019 |
| 298 | CAST | Active Monitoring of Cancer As An Alternative To Surgery | 2019 |
| 299 | PAVE | A nanovaccine Approach for the treatment of Pancreatic Cancer | 2019 |
| 300 | AlternativesToGd | Hyperpolarised MR technologies and molecular probes as alternatives for conventional metal-containing contrast agents for MRI examinations | 2019 |
| 301 | ORIGIN | Optical Fibre Dose Imaging for Adaptive Brachytherapy | 2020 |
| 302 | Miiskin | ML-powered app and platform to identify skin changes over time | 2019 |
| 303 | RARITY | RAtional design of canceR ImmunoTherapY: one size does not fit all | 2019 |
| 304 | InflaPML | Promyelocytic leukemia protein (PML) outside the tumor: a new player in the control of inflammation | 2020 |
| 305 | PRISAR2 | proactive monitoring of cancer as an alternative to surgery | 2020 |
| 306 | STI-001 | Turn Cancer Immunotherapy Effective in Most Patients | 2019 |
| 307 | NUCDDR | Nucleolar Responses to DNA Damage: rDNA, an emerging hub of genome instability | 2020 |
| 308 | GenomtecTumor | MicroRNA-based tool for non-invasive early-stage cancer diagnosis | 2019 |
| 309 | ENDOWAVE | ENDObronchial microWAVE Ablation for the minimally invasive treatment of lung cancer | 2019 |
| 310 | oncNGS | NGS diagnostics in 21st century oncology: the best, for all, at all times | 2020 |
| 311 | SIROCCO | Remote control of cellular signalling triggered by magnetic switching | 2020 |
| 312 | HyperCube | HyperCube: Gram scale production of ferrite nanocubes and thermo-responsive polymer coated nanocubes for medical applications and further exploitation in other hyperthermia fields | 2020 |
| 313 | PROSTATOR | Reliable urinary test for the diagnosis of prostate cancer | 2020 |
| 314 | NIMBUS4CIP | Effective management of pregnant cancer patients through a cloud-based integrative and highly specialized advisory board platform | 2020 |
| 315 | ALTER-brain | Metastasis-associated altered molecular patterns in the brain | 2020 |
| 316 | KineTic | New Reagents for Quantifying the Routing and Kinetics of T-cell Activation | 2020 |
| 317 | NanoBioMade | Bioinorganic intracellular synthesis of photo-responsive bio-camouflaged nanomedicines | 2021 |
| 318 | BRCAstem | Monitoring cancer stem cell dynamics and therapeutic response in BRCA2-deficient breast tumour cells | 2020 |
| 319 | NANOCRISPR | NANODELIVERY OF SPECIFIC GENOME ENGINEERING TOOLS AS A NOVEL THERAPEUTIC APPROACH FOR AGGRESSIVE PROSTATE CANCERS | 2021 |
| 320 | PDASwITch | Super-enhancer modules controlling plasticity and response to therapy in pancreatic cancer | 2020 |
| 321 | PRECISMEDLYM | Aggressive T cell Lymphomas, integrated clinical and genomic analysis for a precision medicine. | 2020 |
| 322 | RCC_Evo | Modelling the Predictability and Repeatability of Tumour Evolution in Clear Cell Renal Cell Cancer | 2020 |
| 323 | MRTFSen | MRTF/SRF signalling in regulation of cell senescence and melanoma progression | 2020 |
| 324 | COSMOS | The Conformation Of S-phase chroMOSomes | 2020 |